By Brazil Stock Guide – Oncoclínicas (B3: ONCO3) said it received a formal request from Latache-managed funds, which hold 14.6% of the company’s capital, to call an extraordinary shareholders’ meeting aimed at removing the entire board of directors and electing a new slate for a unified two-year term. The move, submitted on November 25 and disclosed by the company today, puts immediate pressure on the group’s governance structure.
Latache IV, Nova Almeida and Latache MHF I asked shareholders to vote on six agenda items, including defining the board size, assessing the independence of nominees, electing new directors and choosing the chair and vice-chair among those elected. Oncoclínicas said only that it will follow all legal and bylaw requirements and keep investors informed of developments.
The company’s statement offered a single formal line acknowledging the request: “The Company’s management will proceed with the request to convene an extraordinary shareholders’ meeting, in accordance with the applicable legal and statutory deadlines.”
The move also unfolds against a broader backdrop of tensions between Latache and Oncoclínicas. Latache has been pushing for greater influence since questioning — including in court — the transparency of the company’s 2021 IPO disclosures and Goldman Sachs’s subsequent sale of its stake to Centaurus.
The firm argues that the transaction raised doubts about potential tender-offer triggers and the true control structure of the company, adding another layer to the confrontation that now culminates in the call for a full board overhaul.
Leave a Reply